Skip to main content
. 2022 Jun 28;13:885424. doi: 10.3389/fimmu.2022.885424

Figure 2.

Figure 2

Characterization of anti-CLDN18.2 hu7v3-Fc. (A) Flow cytometric analysis to determine the specificity of hu7v3-Fc to CLDN18.2. Zolbetuximab was employed as the positive control antibody, and human IgG1 isotype as the negative control antibody. CLDN18.1 and CLDN18.2 was co-expressed with GFP in CHO-CLDN18.1-GFP and CHO-CLDN18.2-GFP cells, respectively. (B) IHC analysis to determine the specificity of hu7v3-Fc to CLDN18.2. Frozen sections of colon, brain, lung, lymph node, ovary, skin parotid gland, kidney, liver, pancreas, stomach antrum and stomach body were obtained from healthy tissue in The First Affiliated Hospital of Zhejiang University.